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Abstract
Background—Since 2006, the government of Kenya began decentralizing HIV care from 
secondary health facilities (SHF) to an expanded network, including primary health facilities 
(PHF). We evaluated the impact of this strategy on enrollment, care, and outcomes among adult 
patients in Central Province, Kenya, from 2006 to 2010.
Methods—We analyzed electronic patient-level data for 26,690 patients at 15 SHF and 22 PHF. 
Enrollment, patient, and facility characteristics and patterns in CD4+ testing, World Health 
Organization staging, and antiretroviral treatment (ART) initiation were compared between SHF 
and PHF. Survival analysis was used to estimate cumulative death and loss to follow-up (LTF) 
rates in PHF and SHF. Multivariate competing risks regression and Cox proportional hazards 
models were constructed to identify correlates of LTF and death.
Results—Enrollment in PHF increased mainly between 2007 and 2009, representing 5% and 
25% of all new enrollments, respectively. CD4+ test provision and World Health Organization 
staging, time to ART initiation, and CD4+ count at ART initiation were for the most part similar 
between PHF and SHF. In multivariate analyses, pre-ART patients enrolled in PHF had a lower 
risk of LTF than those enrolled in SHF (SHR = 0.77, 95% confidence interval: 0.61 to 0.96). No 
differences in risk of death among pre-ART patients or in LTF or death among ART patients were 
observed.
Conclusions—Enrollment at PHF increased substantially during the period; death rates were 
comparable between PHF and SHF, whereas LTF among pre-ART patients was lower at PHF. This 
suggests that decentralization can be a successful strategy for expanding HIV care.
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INTRODUCTION
Kenya is one of the countries in the world most severely affected by the HIV epidemic. With 
an estimated adult HIV prevalence of 5.6%, there are an estimated 1.2 million people living 
with HIV in Kenya.1 According to the 2012 Kenya AIDS Indicator Survey, fewer than half 
of all HIV-infected adults in Kenya know their HIV status and less than two-thirds of 
individuals eligible for therapy are on antiretroviral treatment (ART).1 More than 75% of 
Kenyans live in rural areas, and, in recent years, estimated HIV prevalence in rural areas has 
begun to reach levels estimated within urban settings—suggesting that the population in 
need of HIV care in Kenya is largely, and increasingly, rural.2
Initial efforts to provide HIV care and treatment throughout Kenya focused on large 
secondary health facilities (SHF), such as provincial and district hospitals often located in 
non-rural areas. To improve patient access to services and reduce staff burden in large 
facilities, HIV services have been dramatically expanded through a strategy of 
decentralization from 15 health facilities—mainly SHF—in 2003 to over 700 facilities by 
December 2008.3 An essential part of this process has been the establishment of HIV clinics 
at smaller primary health facilities (PHF), such as health centers and dispensaries. The aim 
of decentralization was to achieve universal HIV care and treatment by providing services 
close to those in need, in a sustainable fashion. It was also expected that decentralization 
would foster integration of HIV programs with other services provided at the health facilities 
and result in improved quality of services and patient care.3
A small body of research has generally found that decentralization of adult HIV care in sub-
Saharan Africa has been successful in attracting patients to peripheral facilities, and 
retaining them in care at least, and to large secondary facilities.4–8 Although encouraging, 
these analyses have, however, largely relied on routine programmatic data among patients 
receiving ART and have often not examined key indicators of the quality of care provided, 
such as routine assessments of patients for ART eligibility and subsequent initiation of 
patients on ART once eligible; furthermore, the success of decentralizing HIV care in Kenya 
remains to be characterized. Therefore, more evidence is needed to understand the 
effectiveness of decentralization in expanding access to quality HIV services.
In this analysis, we compared key adult patient and facility characteristics, measures of the 
quality of routine care provided (eg, CD4+ testing, time to ART initiation), and patient death 
and loss to follow-up (LTF) among adults >15 years of age enrolled in HIV care in SHF and 
PHF in Central Province, Kenya, during the period 2006–2010, with patient follow-up time 
observed through 2011.
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METHODS
Study Design and Study Population
This study was conducted through analyses of clinical program data collected routinely as a 
part of HIV care and treatment services in Kenya and of data on facility characteristics 
collected annually between 2006 and 2010. The facilities included in this analysis were 
supported by ICAP-Columbia University (ICAP) through funding from the President’s 
Emergency Plan for AIDS Relief.9 Clinics included in this analysis were the 37 Ministry of 
Health (MOH) facilities in Central Province that routinely entered patient-level HIV care 
data into an electronic patient-level database. In Central Province, the number of MOH 
facilities providing HIV care expanded from 14 in 2006 to 52 by the end of 2010; during this 
time, 42,863 persons were enrolled in HIV care.10 Across the 37 facilities included in this 
analysis, 26,690 persons enrolled in HIV care between 2006 and 2010, which constitutes 
62% of all patients enrolled in care across all 52 MOH sites in Central Province during the 
period.
The source of the clinical patient data was the MOH Comprehensive Care Clinic Patient 
Card (MOH 257), which was completed by facility health workers at every patient visit. This 
included patient demographic and clinical data, laboratory test results, treatment including 
ART, and key mortality and morbidity outcomes. Updated contents of the patient card were 
entered on-site by data clerks into an electronic patient-level database on a routine basis.
Clinic and Program Characteristics
Information on characteristics of facilities and programs was collected annually, beginning 
in 2006, using a structured questionnaire for each HIV care facility. Questionnaires were 
completed by ICAP staff, based on observations and on interviews with facility staff. 
Information collected included the range of clinical and support services provided, HIV 
clinic staffing levels by cadre, location type, and facility type. Location types could include 
urban city (officially designated to be a city, with city administration and political bodies), 
semi-urban (big and small towns, peri-urban areas, growth points, mining communities), and 
rural (village, subsistence farming areas, large- and small-scale commercial farming areas) 
settings. Facility types were defined as public primary (health center clinic), public 
secondary (district/provincial hospital), public tertiary (teaching/national referral hospital), 
or private (any facility run by private, nongovernmental, or faith-based organization) 
facilities. In this analysis, public primary facilities were defined as PHF and public 
secondary facilities as SHF—no public tertiary or private facilities were supported by ICAP 
and collecting electronic patient-level data during the period examined.
Guidelines for HIV Care and ART
Kenya MOH national ART guidelines released in 2005 recommended initiation of ART for 
all adult patients evaluated as World Health Organization (WHO) stages 1 and 2 with a 
CD4+ cell count (CD4+) <200 cells per cubic millimeter; for patients with WHO stage 3 and 
CD4+ <350 cells per cubic millimeter; and for all patients determined to be WHO stage 4.11 
Additionally, where CD4+ testing was not available, all patients assessed as WHO stage 3 or 
4 were recommended to initiate ART. Updated ART guidelines were released by the Kenya 
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MOH in November 2011 and therefore largely do not apply to the patient visits observed in 
our analysis.12
Statistical Methods
Patient- and facility-level characteristics at enrollment and at ART initiation were described 
and compared between PHF and SHF. Adult patients enrolled at 1 of the 37 facilities 
between 2006 and 2010 were included in this analysis, with follow-up data for these patients 
available through 2011.
Description of the Decentralization Process—Total number and percentage of active 
patients and new enrollments at PHF and SHF were calculated for each calendar year to 
show the secular trend of decentralization. The total number of the PHF and SHF that 
initiated HIV care services was also presented.
Patient- and facility-level characteristics at enrollment and at ART initiation were described 
and compared between PHF and SHF. Facility-level characteristics included calendar year 
when the facility initiated HIV services, facility location, whether the facility had a CD4 
machine on-site and nurses initiating ART or prescribing ART, and the patient-to-provider 
ratio. Annual provider–patient ratio was calculated for each facility, each year, as the sum of 
the full-time–equivalent (FTE) number of physicians, nurses, and clinical officers divided by 
the number of patients who had at least one visit during the respective calendar year at the 
facility. (Only staff time dedicated to HIV care patients was included in this measure.) 
Patient-level characteristics included sex, age, point of entry to HIV care, CD4+, and WHO 
stage at enrollment and at ART initiation for ART patients. The frequencies of categorical 
variables were compared using χ2 tests, and the mean values of continuous variables were 
compared using Student t tests.
Quality of Care, Patient Outcomes, and the Impact of Decentralization—The 
proportion of patients with ART eligibility assessed at enrollment and at 3 and 6 months 
after enrollment were calculated and compared between patients in PHF and SHF. Among 
patients who were eligible for ART at enrollment, the proportion of patients who initiated 
ART and the median time to ART initiation were also compared between the 2 groups.
Lost to follow-up and death curves were estimated using survival analyses. Bivariate and 
multivariate models were fitted to identify whether decentralization from SHF to PHF had 
any impact on patient outcomes at both pre-ART and post-ART stages. The pre-ART stage 
was defined as the time from patient enrollment into care to the end of follow-up or the 
event, including death, lost to follow-up, transfer out, or ART initiation. The multivariate 
model adjusted for age, gender, marital status, CD4+ and WHO stage at enrollment or ART 
initiation, and calendar year of enrollment into HIV care or ART initiation. Kaplan–Meier 
and Cox regression models were used for patients on ART, and competing risks methods 
were used for the pre-ART analysis, treating ART initiation as the competing risk for death 
and LTF. Hazard ratios were calculated for the ART analyses, and subhazard ratios were 
calculated for the pre-ART analyses.13 A robust variance estimate was used to adjust for 
within-site correlations.14,15 All analyses were done using SAS 9.3 and Stata 12.1.
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Ethical Approval
All data were de-identified before analysis, and the investigators had no access to 
identifiable patient information. Institutional review board approval was obtained from the 
Kenya Medical Research Institute; the study was designated nonhuman subject research by 
the Institutional Review Board of Columbia University; the Center for Global Health at the 
US Centers for Disease Control and Prevention determined the study to not involve 
engagement in human subject research.
RESULTS
Facility and Program Characteristics
Beginning in 2007, the number of SHF-enrolling patients remained constant at 15 facilities, 
whereas the number of PHF-enrolling patients increased from 1 before 2007, to 3 in 2007, 
13 in 2008, 21 in 2009, and 22 in 2010 (Table 1). The annual number of patients enrolling in 
HIV care at SHF peaked in 2007 (5757) and declined each subsequent year. Annual 
enrollment at PHF plateaued in 2009 and 2010 (1262 and 1265). Over time, the proportion 
of all new HIV care patients who were enrolled in a PHF also increased, with the majority of 
increase occurring between 2007 and 2009. For the last year observed, 2010, 26% of new 
HIV care patients enrolled at a PHF, whereas the remaining 74% of patients enrolled at an 
SHF.
The SHF were nearly evenly divided between rural (53%) and semi-urban areas of Central 
Province (Table 1). The PHF were almost exclusively (95%) located in rural areas. Since 
2007, 40% of SHF had a CD4 machine located on-site; during any given year, a maximum 
of only 2 (10%) PHF reported having a CD4+ machine on-site. Nearly all SHF (93%) and all 
PHF (100%) reported nurse-led ART eligibility assessment and prescription of ART at some 
point across the period observed (2009–2010). The mean annual provider-to-patient ratio for 
total clinical staff in SHF ranged from 0.5 to 1.3 FTE providers per 100 patients for all 
periods. The mean ratio for PHF each year except one was dramatically higher than SHF, 
ranging from 1.8 to 8.6 since 2008 (as compared with 0.5–0.6 for SHF) (P < 0.001 for each 
year except 2007). The mean annual provider-to-patient ratio limited to physicians ranged 
from 0.004 to 0.3 FTE providers per 100 patients in SHF. No physician staffing was reported 
for any PHF between 2007 and 2010.
Patient Characteristics, Quality of Care, and Outcomes
Across the period observed, a total of 26,690 patients enrolled in HIV care and 15,877 
initiated ART in 1 of the 37 facilities. For both SHF and PHF, the populations enrolling in 
care were predominately female (69.3%); the age structure of the 2 types of facilities was 
also similar (Table 2). Patients of PHF were, however, more likely to have transferred into 
the facility than were patients of SHF (19.8% at PHF vs. 12.1% at SHF; P < 0.0001).
Overall, 41% of patients did not have any CD4+ test results at the time of enrollment in care 
recorded. The proportion of patients missing CD4+ test results was highest in the earlier 
years examined (including 73% of PHF patients and 67% of SHF patients missing CD4+ 
results in 2006) and declined each year to approximately 25% in 2011. Among patients with 
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CD4+ test results at enrollment, a somewhat higher proportion of SHF patients had a CD4+ 
<100 cells per cubic millimeter (31% vs. 25%) (P < 0.001 comparing all categories). 
Patients who had transferred in from another facility were less likely than non–transfer-in 
patients to have an enrollment (post-transfer) CD4+ >350 cells per cubic millimeter (18% vs. 
29%); this general pattern was consistent for patients transferring into PHF (18% vs. 34%) 
and SHF (18% vs. 28%). Among the 77% of patients with a WHO stage at enrollment, a 
substantially higher proportion of PHF enrollees were recorded as stage 1 (39% vs. 26%), 
whereas SHF had higher proportions recorded for each stage 2–4 (P < 0.0001). By 6 months 
after enrollment in care, a somewhat greater proportion of patients in PHF (71%) compared 
with SHF (65%) had adequate immunologic or clinical staging information to determine 
ART eligibility (P < 0.001) (Table 3). Among patients who were assessed for ART eligibility 
in the first 6 months of care, a lower proportion of PHF (55%) than SHF (65%) were found 
to be ART eligible (P < 0.001), and, among those patients, an equal proportion (37%) of 
PHF and SHF patients initiated ART within 30 days. By 6 months after ART eligibility was 
determined, 71% of these patients in PHF and 65% in SHF had started ART (P < 0.001).
Among all patients who ultimately initiated ART, only a minority (18%) had missing CD4+ 
test results at the time of ART initiation (Table 2). Annual median CD4+ at ART initiation 
also increased across the years observed; however, these did not differ significantly between 
SHF and PHF, with the exception of 2009, when the median value for PHF was higher (P < 
0.0001) (data not shown).
Across the period examined, cumulative mortality among patients in pre-ART did not 
exceed 8% and no significant difference was observed between SHF and PHF (Fig. 1A). 
Large differences were, however, recorded in the frequency of patients identified as LTF 
after enrollment in care—with cumulative LTF reaching 19.3% in SHF by 6 months and 
11.3% at this same point in time among PHF patients. This absolute gap in cumulative LTF 
of about 10% between PHF and SHF established in the first 6–9 months after enrollment 
was observed to remain roughly constant across the remaining years observed.
Among patients initiating ART, slightly higher cumulative mortality was observed 
(approximately 5% at 12 months) than among pre-ART patients, again with no difference in 
mortality between SHF and PHF (Fig. 1B). LTF after ART initiation, unlike the period after 
enrollment in care, did not occur mainly within the first 6 months. Rather, the rate of LTF 
seemed to be relatively constant. Six-month cumulative LTF after ART initiation was 7.4% 
for SHF patients and 4.7% for PHF patients; this small absolute gap remained roughly 
constant across the period observed.
Association of Site Type With LTF and Death
Results of multivariate regression models (Table 4) indicate that the facility type (PHF vs. 
SHF) was not substantially correlated with death among pre-ART patients. However, 
enrollment in a PHF was significantly associated with a lower risk of LTF among pre-ART 
patients [adjusted subhazard ratio (SHR) = 0.77, 95% confidence interval: 0.62 to 0.97]. 
Among ART patients, site type was not clearly associated with death or LTF.
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DISCUSSION
These findings provide the first broad assessment of decentralization process in Kenya. They 
also present a unique contribution to the literature on decentralization in that they evaluate 
patient enrollment and outcomes not only among patients on ART but also for patients 
during the pre-ART stage of care. The results at the same time provide support for some of 
the key themes in an emerging body of literature on decentralization of HIV care. Namely, 
we observed a substantial increase in patient enrollment at PHF and generally comparable or 
reduced rates of death and LTF at these facilities as compared with SHF during 2006–2011. 
Measures of the quality of care provided—including CD4+ test provision and WHO staging, 
time to ART initiation, and CD4+ count at ART initiation—were for the most part similar 
between PHF and SHF, though a higher proportion of eligible PHF patients initiated ART 
within 6 months. Differences may have been in part facilitated by the higher staffing levels 
(provider–patient ratios) observed at PHF. We also observed that patients enrolling in HIV 
care at PHF on average were less immunosuppressed than new patients at SHF, as measured 
by CD4+ cell count at care initiation, and a substantial proportion of new PHF patients were 
transfers-in from another HIV care facility.
Although our findings are in general consistent with the results showing comparable or 
superior retention in decentralized clinics, all previous published studies have shown 
reduced LTF and several showed lower death rates among ART patients,4–8 which our 
findings did not. In this case, we observed no difference in LTF or death rates among ART 
patients but rather lower LTF at PHF only among pre-ART patients (previous studies were 
limited to ART patients). One likely contributing factor to our study not finding lower LTF 
in PHF among ART patients is that, which 12-month LTF among PHF patients in our study 
was similar to that observed in several other studies, LTF among SHF patients was at least 
slightly lower (in some cases substantially lower) than that reported for other studies.4–8 
This may in part have to do with programmatic differences—for example, Bedelu et al6 
reported that the SHF included in their analysis did not at the time employ staff to follow-up 
with patients who defaulted. In addition, 12-month death rates among ART patients of SHF 
in our analysis seem to be in general substantially lower than the rates at comparable 
facilities reported in other studies.4–8
Our findings on staffing levels concur with Boyer et al,16 who also reported dramatically 
smaller patient loads for providers in decentralized clinics. The potential impact of the 
overall staffing-level disparities between PHF and SHF on quality of patient care and patient 
outcomes is unclear. The research by Boyer et al16 also found that patients at peripheral sites 
are more likely to encounter shorter wait times, which may in part be a function of higher 
provider-to-patient ratios. Numerous other studies have identified long clinic wait times as a 
key barrier to retention in HIV care.17 Other key factors promoting retention in PHF may be 
related to the presumably shorter distance between patient homes and facilities, including 
reduced travel time and transport costs, which have also been cited as main contributors 
toward LTF.17,18
The existing published research on HIV care decentralization does not present information 
on levels of immunosuppression at entry to HIV care, and only one published study 
Reidy et al. Page 7
J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2016 November 14.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
compared CD4+ at ART initiation.7 The somewhat healthier profile of newly enrolling 
patients at PHF we observed is consistent with the premise that complicated advanced HIV 
cases are seen at larger better capacitated facilities.3,5 It is unclear to what extent the lower 
frequency of advanced HIV cases enrolling at PHF is a result of patient self-selection, with 
sicker patients choosing to attend SHF, and of PHF providing more accessible care (possibly 
because of location, size, staffing, and other factors) resulting in earlier HIV care initiation 
after diagnosis. Our observation that patients initiating ART at a PHF were less likely to 
have a CD4+ <100 cells per cubic millimeter may be a result of patients presenting for care 
at PHF somewhat healthier; more routine ascertainment of ART eligibility at PHF —with a 
slightly higher proportion of patients in PHF having their eligibility for ART determined 
within the first 6 months of care; and/or PHF patients having a greater likelihood of starting 
ART in the months after determination of eligibility, as we also observed. It does not, 
however, seem to be a result of healthier patients being transferred disproportionately to 
PHF.
Perhaps surprising is the lack of clear relationship between availability of a CD4+ machine 
on-site at SHF compared with PHF—SHF far more commonly had CD4+ machines—and 
the percentage of patients with CD4+ test results at enrollment and ART initiation, which did 
not differ by site type. This may reflect a level of success in establishing an effective 
laboratory network, as was called for in the Kenya decentralization guidelines,3 in Central 
Province. This success should, however, be noted within the context of a large proportion of 
CD4+ test results not available for new patients in SHF and PHF; it is possible that the 
burden of supporting CD4+ testing for patients enrolled elsewhere has impeded routine 
CD4+ testing at facilities with CD4+ machines, perhaps through issues such as rationing of 
equipment and staff time and stock-outs of supplies such as reagents.
The data included in this analysis were limited to 37 of the 52 MOH facilities in Central 
Province, and therefore, findings may not be generalizable to all MOH facilities in the 
province. This analysis relied on program data as opposed to rigorously collected research 
data, and although data quality assessments were conducted routinely to improve data 
completeness and accuracy, the data had a degree of incompleteness and inaccuracy. In 
particular, it is recognized that programmatic data may commonly overstate the degree of 
patient LTF and understate transfers-out and deaths.19 Furthermore, it is also possible that 
systems for collecting and recording information affecting measures of retention—including 
documentation of transfers-out of facilities and routine tracing of defaulters and updating of 
outcome status (eg, death)—are not of comparable quality across SHF and PHF, which 
would affect the validity of our findings. Lastly, some proportion of missing CD4+ results 
were likely a result of incompleteness in data entry rather than reflecting tests not done; 
whether this problem occurred with differing frequency in PHF and SHF is not known.
CONCLUSIONS
The first few years of decentralization of HIV care in Central Province have shown 
increased access to crucial HIV care and treatment services. In addition, the data presented 
here suggest that the quality of services at PHF is in the very least comparable to the quality 
of services provided at SHF. Further studies are needed to confirm these findings and assess 
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the long-term effects of decentralization on provision of care, quality of services, and 
acceptance by persons living with HIV.
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FIGURE 1. 
Kaplan–Meier graphs showing probability of death and LTF for 3 years after enrollment in 
HIV care among (A) pre-ART and (B) ART patients, by facility type, PHF, or SHF.
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TABLE 1
Facility Characteristics, by Facility Type
PHF (n = 22 Facilities) SHF (n = 15 Facilities)
Number of facilities initiating HIV services, n (%)
 ≤2006 1 (4.5) 13 (86.7)
 2007 2 (9.0) 2 (13.3)
 2008 10 (45.5) 0 (0.0)
 2009 8 (36.4) 0 (0.0)
 2010 1 (4.5) 0 (0.0)
Number of patients enrolling in HIV care, n (%)*
 2006 148 (3.4) 4203 (96.6)
 2007 389 (6.3) 5757 (93.7)
 2008 817 (14.0) 5016 (86.0)
 2009 1262 (23.0) 4216 (77.0)
 2010 1265 (25.9) 3617 (74.1)
Location of facility, n (%)
 Semi-urban 1 (4.5) 7 (46.7)
 Rural 21 (95.5) 8 (53.3)
Facility had a CD4 machine on-site, n (%)
 2006 1 (4.5) 3 (20.0)
 2007 1 (4.5) 6 (40.0)
 2008 1 (4.5) 6 (40.0)
 2009 2 (9.0) 6 (40.0)
 2010 2 (9.0) 6 (40.0)
Nurse provision of ART at facility, n (%)†
 ART eligibility assessed by nurses
  2009 21 (95.5) 14 (93.3)
  2010 21 (95.5) 14 (93.3)
 ARV prescription by nurses at ART initiation
  2009 22 (100.0) 14 (93.3)
  2010 22 (100.0) 13 (86.7)
Provider–patient ratio (total clinical staff FTE/100 patients, mean (range)‡§
 2006 8.6 (0–25.0) 1.1 (0.2–6.1)
 2007 3.0 (0.7–8.3) 1.3 (0.2–8.7)
 2008 1.8 (0.4–5.0) 0.6 (0.1–2.0)
 2009 2.6 (0.5–6.7) 0.5 (0.3–1.2)
 2010 2.6 (0.5–6.7) 0.5 (0.1–1.3)
Provider–patient ratio (physician staff FTE/100 patients, mean (range)
 2006 1.4 (0–3.4) 0.3 (0–3.0)
 2007 0 (0–0) 0.1 (0–0.3)
 2008 0 (0–0) 0.1 (0.1–0.2)
 2009 0 (0–0) 0.004 (0–0.06)
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PHF (n = 22 Facilities) SHF (n = 15 Facilities)
 2010 0 (0–0) 0.03 (0–0.2)
*
Percentage shows percentage of total annual enrollment per site type (row percentage).
†Nurse provision of ART was not assessed before 2009.
‡
FTE staff = number of staff hours for nurses, physicians, and clinical officers/40 hours.
§
Differences in total clinical staff provider–patient ratio between PHF and SHF were significant (P < 0.001) for each year except 2007.
ARV, antiretroviral.
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TABLE 3
ART Eligibility Determination and Timing of ART Initiation, by Facility Type
PHF (n = 3881) SHF (n = 22,809)
n (%) n (%) P
Patients with ART eligibility ascertained:
 At enrollment in HIV care* 2246 (57.9) 12,402 (54.4) <0.001
 Within first 3 mo of HIV care 2601 (67.0) 14,162 (62.1) <0.001
 Within first 6 mo of HIV care 2768 (71.3) 14,854 (65.1) <0.001
Patients determined to be ART eligible within first 6 mo of HIV care 1521 (54.9†) 9647 (64.9†) 0.0003
Among patients who were ART eligible at enrollment* 1268 (56.5‡) 8208 (66.2‡) <0.0001
 Initiated ART within 30 days 472 (37.2) 3060 (37.3) 0.97
 Initiated ART within 6 mo 910 (71.8) 5181 (63.1) <0.0001
*ART eligibility at enrollment was ascertained using CD4 and WHO staging information collected within 90 days before and 30 days after the 
enrollment date.
†
Percentage among patients with eligibility ascertained.
‡
Percentage of patients screened for ART eligibility who were determined to be eligible at enrollment.
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TABLE 4
Associations Between Attending a PHF and Death Among Pre-ART and ART Patients (N = 15,877)
Crude SHR* 95% CI Adjusted SHR* 95% CI
Pre-ART
 Death 0.82 0.59 to 1.13 1.28 0.90 to 1.82
 LTF 0.62 0.42 to 0.93 0.77 0.62 to 0.97
ART
 Death 0.91 0.66 to 1.25 0.94 0.67 to 1.32
 LTF 0.72 0.34 to 1.55 0.67 0.27 to 1.65
*
Reference category: SHF. Adjusted models control for WHO stage, CD4 count, age group, gender, year of patient enrollment in care, or ART 
initiation.
CI, confidence interval; SHR, subhazard ratio.
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